Nomenclature
Short Name:
NME2
Full Name:
Nucleoside diphosphate kinase B
Alias:
- c-Myc purine-binding transcription factor PUF
- c-myc purine-binding transcription factor PUF
- NDP kinase B
- NDPKB
- NM23B
- NM23-H2; Non-metastatic cells 2, protein (NM23B) expressed in Kinase (non-protein); Nucleotide Metabolism - pyrimidine; Nucleotide Metabolism - purine; EC 2.7.4.6
- c-myc purine-binding transcription factor PUF
- EC 2.7.4.6
- NDK B
- NDKB
Classification
Type:
Protein-serine/threonine kinase
Group:
Atypical
Family:
SubFamily:
NA
Specific Links
Structure
Mol. Mass (Da):
17298
# Amino Acids:
152
# mRNA Isoforms:
2
mRNA Isoforms:
30,137 Da (267 AA; P22392-2 (P15531 isoform 3)); 17,298 Da (152 AA; P22392)
4D Structure:
1D Structure:
3D Image (rendered using PV Viewer):
PDB ID
Subfamily Alignment
Domain Distribution:
| Start | End | Domain |
|---|
Post-translation Modifications
For detailed information on phosphorylation of this kinase go to PhosphoNET
Acetylated:
K12, K26, K31, K49, K56, K66, K85, K100, K124, K128, K143.
Other:
H118 (histidine phosphorylation; .
Serine phosphorylated:
S44, S99, S120, S122, S131.
Threonine phosphorylated:
T94, T103.
Tyrosine phosphorylated:
Y52, Y142, Y151.
Ubiquitinated:
K12, K26, K31, K39, K49, K56, K66, K85, K100, K124, K128, K135.
Distribution
Based on gene microarray analysis from the NCBI
Human Tissue Distribution
% Max Expression:
Mean Expression:
Number of Samples:
Standard Deviation:
% Max Expression:
Mean Expression:
Number of Samples:
Standard Deviation:
24
1513
16
1316
12
714
14
390
13
828
5
805
16
1006
54
519
20
1225
14
715
9
545
37
217
15
948
27
770
13
796
29
685
14
852
10
413
8
491
77
429
9
547
26
492
13
784
155
714
6
370
16
399
9
539
15
442
11
658
19
506
8
486
10
180
7
458
275
506
17
1064
16
1110
9
535
73
575
16
974
56
705
8
504
22
376
10
593
24
597
8
504
14
705
5
284
16
148
8
469
22
354
16
969
32
846
11
697
19
675
13
819
16
792
12
741
16
650
6
398
14
54
14
878
42
678
10
592
21
706
100
6201
57
5108
17
1027
31
693
2
135
22
122
Evolution
Species Conservation
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
100
100
100
46.4
47.7
0
57
60.8
-
-
-
93
-
-
-
84.8
92.1
92
-
-
-
98
99.3
98
98
99.3
98
-
-
-
54.3
55.8
-
91.5
96
93
86.3
94.8
86
86.9
92.8
80
-
-
-
77.1
86.2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
61
40
51
-
60.1
79
-
63.1
79.6
-
For a wider analysis go to PhosphoNET Evolution in PhosphoNET
Regulation
Activation:
NA
Inhibition:
NA
Synthesis:
NA
Degradation:
NA
Known Downstream Substrates
For further details on these substrates click on the Substrate Short Name or UniProt ID. Phosphosite Location is hyperlinked to PhosphoNET
predictions.
Based on in vitro and/or in vivo phosphorylation data
| Substrate Short Name | UniProt ID (Human) | Phosphosite Location | Phosphosite Sequence | Effect of Phosphorylation |
|---|
Disease Linkage
General Disease Association:
Cancer
Specific Cancer Types:
Acute myelogenous leukemias (AML)
Comments:
NME2 is linked to Acute myeloid leukemia (AML), which is a rare blood cancer disease in which healthy blood cells are displaced and can lead to fever, shortness of breath, fatigue, and easy bruising.
Gene Expression in Cancers:
TranscriptoNET (www.transcriptonet.ca) analysis with mRNA expression data retrieved from the National Center for Biotechnology Information's Gene Expression Omnibus (GEO) database, which was normalized against 60 abundantly and commonly found proteins, indicated altered expression for this protein kinase as shown here as the percent change from normal tissue controls (%CFC) as supported with the Student T-test in the following types of human cancers: Bladder carcinomas (%CFC= +243, p<0.0008); Classical Hodgkin lymphomas (%CFC= +248, p<0.0001); Colon mucosal cell adenomas (%CFC= +165, p<0.0001); Gastric cancer (%CFC= +71, p<0.0002); Large B-cell lymphomas (%CFC= +279, p<0.0003); Lung adenocarcinomas (%CFC= +94, p<0.004); Malignant pleural mesotheliomas (MPM) tumours (%CFC= +58, p<0.0001); Oral squamous cell carcinomas (OSCC) (%CFC= +53, p<0.001); Ovary adenocarcinomas (%CFC= +76, p<0.093); Prostate cancer (%CFC= +61, p<0.056); Prostate cancer - metastatic (%CFC= +52, p<0.0002); Skin fibrosarcomas (%CFC= +154); Skin melanomas - malignant (%CFC= +203, p<0.0001); T-cell prolymphocytic leukemia (%CFC= +95, p<0.046); Uterine leiomyomas (%CFC= +199, p<0.007); and Vulvar intraepithelial neoplasia (%CFC= +48, p<0.004). The COSMIC website notes an up-regulated expression score for NME2 in diverse human cancers of 513, which is 1.1-fold of the average score of 462 for the human protein kinases. The down-regulated expression score of 125 for this protein kinase in human cancers was 2.1-fold of the average score of 60 for the human protein kinases.
Mutagenesis Experiments:
Insertional mutagenesis studies in mice have not yet revealed a role for this protein kinase in mouse cancer oncogenesis.
Mutation Rate in All Cancers:
Percent mutation rates per 100 amino acids length in human cancers: 0.04 % in 24657 diverse cancer specimens. This rate is -43 % lower than the average rate of 0.075 % calculated for human protein kinases in general.
Mutation Rate in Specific Cancers:
Highest percent mutation rates per 100 amino acids length in human cancers: 0.44 % in 603 endometrium cancers tested; 0.36 % in 555 stomach cancers tested; 0.11 % in 1240 large intestine cancers tested; 0.09 % in 710 oesophagus cancers tested; 0.08 % in 864 skin cancers tested; 0.07 % in 942 upper aerodigestive tract cancers tested; 0.05 % in 1433 kidney cancers tested.
Frequency of Mutated Sites:
None > 2 in 19,940 cancer specimens
Comments:
No deletions, insertions or complex mutations are noted on the COSMIC website.